$1.15 Earnings Per Share Expected for Horizon Therapeutics Public Limited (NASDAQ:HZNP) This Quarter

Brokerages expect Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) to announce $1.15 earnings per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Horizon Therapeutics Public’s earnings, with the highest EPS estimate coming in at $1.27 and the lowest estimate coming in at $1.08. Horizon Therapeutics Public posted earnings of $0.03 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 3,733.3%. The business is scheduled to issue its next earnings results before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Horizon Therapeutics Public will report full-year earnings of $5.82 per share for the current fiscal year, with EPS estimates ranging from $5.71 to $5.98. For the next fiscal year, analysts forecast that the company will report earnings of $7.36 per share, with EPS estimates ranging from $7.07 to $7.81. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Horizon Therapeutics Public.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last announced its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.14. Horizon Therapeutics Public had a net margin of 16.57% and a return on equity of 26.66%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $995.90 million. During the same quarter in the previous year, the company posted $1.28 EPS. The company’s revenue was up 36.1% compared to the same quarter last year.

A number of brokerages recently issued reports on HZNP. Oppenheimer began coverage on shares of Horizon Therapeutics Public in a research note on Monday, March 14th. They issued an “outperform” rating and a $140.00 price target for the company. Piper Sandler cut their price target on shares of Horizon Therapeutics Public from $143.00 to $133.00 in a research note on Wednesday, January 26th. Morgan Stanley lifted their target price on Horizon Therapeutics Public from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 2nd. Wells Fargo & Company reissued a “buy” rating and issued a $133.00 target price on shares of Horizon Therapeutics Public in a research report on Friday, April 8th. Finally, Zacks Investment Research raised Horizon Therapeutics Public from a “strong sell” rating to a “hold” rating and set a $104.00 price target on the stock in a research report on Thursday, March 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $133.67.

In related news, EVP Andy Pasternak sold 1,313 shares of Horizon Therapeutics Public stock in a transaction dated Friday, February 18th. The shares were sold at an average price of $94.82, for a total value of $124,498.66. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael A. Desjardin sold 20,214 shares of the stock in a transaction that occurred on Tuesday, April 12th. The shares were sold at an average price of $113.12, for a total transaction of $2,286,607.68. Following the completion of the transaction, the executive vice president now owns 82,346 shares of the company’s stock, valued at $9,314,979.52. The disclosure for this sale can be found here. Insiders sold 580,624 shares of company stock worth $60,865,020 over the last three months. Corporate insiders own 2.50% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Van ECK Associates Corp increased its position in Horizon Therapeutics Public by 18.5% during the fourth quarter. Van ECK Associates Corp now owns 11,212 shares of the biopharmaceutical company’s stock worth $1,208,000 after buying an additional 1,749 shares during the last quarter. Mackenzie Financial Corp lifted its position in shares of Horizon Therapeutics Public by 364.5% during the third quarter. Mackenzie Financial Corp now owns 52,243 shares of the biopharmaceutical company’s stock worth $5,723,000 after purchasing an additional 40,996 shares in the last quarter. Brookfield Asset Management Inc. bought a new stake in Horizon Therapeutics Public in the third quarter valued at about $7,534,000. FDx Advisors Inc. boosted its stake in Horizon Therapeutics Public by 4.0% in the 4th quarter. FDx Advisors Inc. now owns 16,131 shares of the biopharmaceutical company’s stock worth $1,738,000 after purchasing an additional 622 shares during the period. Finally, Vontobel Holding Ltd. increased its stake in Horizon Therapeutics Public by 22.7% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,392 shares of the biopharmaceutical company’s stock valued at $1,467,000 after buying an additional 2,478 shares during the last quarter. Hedge funds and other institutional investors own 88.11% of the company’s stock.

HZNP stock traded up $0.18 during mid-day trading on Wednesday, reaching $114.93. The company had a trading volume of 32,967 shares, compared to its average volume of 1,727,587. Horizon Therapeutics Public has a fifty-two week low of $83.42 and a fifty-two week high of $120.54. The company has a market capitalization of $26.34 billion, a price-to-earnings ratio of 51.67, a price-to-earnings-growth ratio of 1.57 and a beta of 1.12. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.90 and a current ratio of 3.16. The firm has a fifty day simple moving average of $103.70 and a 200 day simple moving average of $104.05.

Horizon Therapeutics Public Company Profile (Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Further Reading

Get a free copy of the Zacks research report on Horizon Therapeutics Public (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.